Dr. Reddy’s Labs focuses on ”market prioritization”
HYDERABAD, India Generic drug maker Dr. Reddy’s Labs plans to exit some of its small finished dosages markets and focus on larger ones, the company has announced.
Dr. Reddy’s said the markets it is leaving account for less than 1% of its topline business. It will instead focus on the large markets where it does about 90% of its business – the United States, India, Germany and the former Soviet Union – as well as 10 to 15 markets in which its finished dosages sales are growing significantly.
“We intend to aggressively step up our presence in our key markets with this strategic prioritization,” Dr. Reddy’s COO Satish Reddy said in a statement. “The market prioritization exercise would lead to redeployment of resources within the organization.”
The company said the realignment is an attempt to consolidate and grow its presence where a strong presence already exists. It did not specify which markets it would leave or how it would affect its workforce.
Teva, Medicis, settle legal disputes over acne medication
JERUSALEM A popular generic drug maker announced Thursday that it has mutually agreed to terminate all legal disputes over an acne medication.
Teva and Medicis Pharmaceutical Corporation said they have agreed to end all legal matters between them relating to Solodyn Extended Release Tablets.
Medicis, an independent specialty pharmaceutical company focused primarily on the treatment of dermatological and aesthetic conditions, has agreed to release Teva from liability arising from any prior sales of its generic Solodyn, which were not authorized by Medicis.
Meanwhile, Teva has confirmed that Medicis’ patents relating to Solodyn (minocycline HCl, USP) are valid and enforceable. As part of the settlement, Teva has agreed to immediately stop all further shipments of generic Solodyn.
Under the terms of the settlement agreement, Teva has the option to market its generic versions of Soldyn 45mg, 90mg and 135mg under the Solodyn intellectual property rights belonging to Medicis commencing in November 2011, or earlier under certain conditions. Additional terms were not disclosed.
Solodyn is indicated to treat inflammatory lesions of non-nodular moderate to severe acne, according to its Web site.
Sharing insulin pens can increase infection risk, FDA says
ROCKVILLE, Md. Use of insulin pens and cartridges to administer insulin to multiple patients could increase the risk of transmitting such viruses as HIV and hepatitis, according to an alert released Thursday by the Food and Drug Administration.
“Insulin pens are designed to be safe for one patient to use one pen multiple times with a new, fresh needle for each injection,” FDA Division of Metabolism and Endocrinology Products deputy director of safety Amy Egan said in a statement. “Insulin pens are not designed and are not safe for one pen to be used by more than one patient, even if needles are changed between patients, due to the risk of transmitting blood-borne pathogens.”
The agency said it became aware of incidents at two hospitals, whose names were not disclosed, involving more than 2,000 people in which insulin cartridges were used to administer insulin to multiple patients, though needles were changed.
The hospitals are contacting patients exposed to shared pens and offering them hepatitis and HIV tests, the FDA said. Some patients who may have been exposed have also tested positive for hepatitis C, though whether they contracted it from the pens remains unknown.